Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company held the 13th meeting of the third Board of Directors and the 10th meeting of the third Supervisory Board on April 11, 2022, and the 2021 Annual General Meeting on May 11, 2022, where it reviewed and approved the proposal regarding the "Draft of the First Employee Stock Ownership Plan of Zhejiang Anglikang Pharmaceutical Co., Ltd." and other related proposals. Specific details can be found in the announcements published by the Company on April 12, 2022, and May 12, 2022, in the designated information disclosure media "Securities Times" and the Giant Tide Information Network (www.cninfo.com.cn).
As the first employee stock ownership plan (hereinafter referred to as "this employee stock ownership plan") will expire on November 2, 2026, in accordance with the "Guiding Opinions on the Pilot Implementation of Employee Stock Ownership Plans by Listed Companies," the "Self-Regulatory Guidelines No. 1 for Listed Companies on the Shenzhen Stock Exchange - Standardized Operations for Main Board Listed Companies," and the relevant provisions of the Company's "Draft of the First Employee Stock Ownership Plan," the listed company is required to disclose a reminder announcement six months prior to the expiration of the employee stock ownership plan. The relevant situation regarding the expiration of the employee stock ownership plan is announced as follows:
1. Basic Information of the Employee Stock Ownership Plan
On November 2, 2022, the Company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. The repurchased shares held in the "Zhejiang Anglikang Pharmaceutical Co., Ltd. Repurchase Special Securities Account" were transferred non-traditionally to the "Zhejiang Anglikang Pharmaceutical Co., Ltd. - First Employee Stock Ownership Plan" special account on November 1, 2022, with a transfer of 2.06 million shares, accounting for 2.15% of the Company's total equity on the transfer date.
On November 15, 2022, and May 19, 2023, the Company implemented the 2022 semi-annual and annual equity distributions, respectively, based on the total equity of the Company at the time of distribution, increasing the capital reserve by 4.5 shares for every 10 shares held by all shareholders. The two equity distributions resulted in an increase of 43,176,068 shares and 262,605,299 shares, respectively. After the completion of the equity distribution, the number of shares held by the first employee stock ownership plan changed to 4,331,150 shares, accounting for 2.15% of the Company's current total equity. Specific details can be found in the announcements published by the Company in the designated information disclosure media "Securities Times" and the Giant Tide Information Network (www.cninfo.com.cn).